Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)

Adjuvant BEP (bleomycin, etoposide, cisplatin) is effective treatment for high-risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT), but the known toxicities of etoposide, and the expansion of the HR group to any patient with vascular invasion (50% of patients), led the Medical R...

Descripción completa

Detalles Bibliográficos
Autores principales: Dearnaley, D P, Fossa, S D, Kaye, S B, Cullen, M H, Harland, S J, Sokal, M P J, Graham, J D, Roberts, J T, Mead, G M, Williams, M V, Cook, P A, Stenning, S P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361823/
https://www.ncbi.nlm.nih.gov/pubmed/15928672
http://dx.doi.org/10.1038/sj.bjc.6602624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361823/
https://www.ncbi.nlm.nih.gov/pubmed/15928672
http://dx.doi.org/10.1038/sj.bjc.6602624

Ejemplares similares